Search

Author/Creator Wasan, H

1. 542PDroplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer. (23rd October 2018)

Authors:
Van Cutsem, E; Lesniewski-Kmak, K; Saunders, M P; Wasan, H; Argiles, G; Borg, C; Creemers, G-J M; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C J A; Stroyakovskiy, D; Ten Tije, A J; van de Wouw, A; Cattan, V; Desachy, G; Amellal, N; Moiseyenko, V M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 74PCommon and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. (23rd October 2018)

Authors:
Madi, A; Fisher, D; Maughan, T S; Colley, J P; Meade, A M; Maynard, J; Humphreys, V; Wasan, H; Adams, R A; Idziaszczyk, S; Harris, R; Kaplan, R S; Cheadle, J P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA-006BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. (2nd July 2019)

Authors:
Kopetz, S; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Gollerkeri, A; Maharry, K; Loupakis, F; Hong, Y; Steeghs, N; Guren, T; Arkenau, H; García Alfonso, P; Sandor, V; Christy-Bittel, J; Anderson, L; Tabernero, J
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018)

Authors:
Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; Ten Tije, A; Van de Wouw, A; Kanehisa, A; Fougeray, R; Busto, N Lopez; Amellal, N; Van Cutsem, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. O-022Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis. (20th June 2018)

Authors:
Lesniewski-Kmak, K; Moiseenko, V; Saunders, M; Wasan, H; Argiles, G; Borg, C; Creemers, G; Fedyanin, M; Glynne-Jones, R; Pfeiffer, P; Punt, C; Stroyakovskiy, D; Ten Tije, A; Van de Wouw, A; Kanehisa, A; Fougeray, R; Busto, N Lopez; Amellal, N; Van Cutsem, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. O-027BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. (20th June 2018)

Authors:
Van Cutsem, E; Cuyle, P; Huijberts, S; Schellens, J; Elez, E; Yaeger, R; Fakih, M; Montagut, C; Peeters, M; Desai, J; Yoshino, T; Ciardiello, F; Wasan, H; Maharry, K; Christy-Bittel, J; Gollerkeri, A; Kopetz, S; Grothey, A; Tabernero, J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P-098TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). (2nd July 2019)

Authors:
Hammel, P; Feliu, J; Parner, V; Berardi, R; Van Cutsem, E; Greil, R; Wasan, H; Metges, J; Nygren, P; Osterlund, P; Seufferlein, T; Creemers, G; Biswas-Baldwin, N; Youssoufian, H; Gupta, A; Salesse, S; Dion, H; El-Hariry, I; Hidalgo, M
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗